Nasdaq: Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer
The Herald News: Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center
Nasdaq: Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Kyverna Therapeutics Highlights Potential of KYV-101 in Multiple Sclerosis with Data from Phase 1 Investigator-Initiated Trials to be Presented at ECTRIMS
Lupus Foundation of America: Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced
An investigator-initiated Phase 1/2 trial of CNTY-101, an investigational therapy, has been announced for the treatment of B-cell mediated autoimmune diseases, including systemic lupus erythematosus ...
Investigator-initiated Study of CNTY-101, for People with Autoimmune Diseases, Including Systemic Lupus Erythematosus and Lupus Nephritis Announced
Morningstar: Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia ...
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients Robust target ...
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia ...
Morningstar: Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study
Cantargia Reports First Patient Dosed in New US Investigator-Initiated Colorectal Cancer Study
The Globe and Mail: Kamada Ltd’s Dependence on Investigator-Initiated Trials Poses Data Integrity and IP Risks to Its Long-Term Growth